BAFF-R CAR-T治疗B细胞肿瘤的研究进展

doi:10.11904/j.issn.1002-3070.2026.01.009

实用肿瘤学杂志 ›› 2026, Vol. 40 ›› Issue (1): 64-68.doi: 10.11904/j.issn.1002-3070.2026.01.009

BAFF-R CAR-T治疗B细胞肿瘤的研究进展

苏帅综述, 肖毅审校

华中科技大学同济医学院附属同济医院血液内科(武汉 430030)

收稿日期:2025-11-10 修回日期:2026-01-05 发布日期:2026-02-27
通讯作者: 肖毅,E-mail:yixiao@tjh.tjmu.edu.cn
作者简介:苏帅,男,(1998—),博士研究生,主要从事血液病的基础及临床研究。
基金资助:
国家自然科学基金项目(编号:82370196)

Research progress on BAFF-R CAR-T therapy for B cell malignancies

SU Shuai, XIAO Yi

Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

Received:2025-11-10 Revised:2026-01-05 Published:2026-02-27

摘要/Abstract

摘要： B细胞活化因子受体(B cell-activating factor receptor,BAFF-R)在多种成熟B细胞来源肿瘤中稳定表达,参与维持肿瘤克隆生存。相对于传统靶点(例如CD19等),BAFF-R更不易因抗原下调或缺失而导致免疫逃逸,是一种具有应用前景的免疫治疗靶点。近年来,针对BAFF-R的细胞免疫治疗已由试验研究逐渐应用于临床,其中BAFF-R 嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)治疗有望成为B细胞肿瘤免疫治疗的重要组成部分。本综述将系统阐述BAFF-R的生物学基础、CAR-T构建策略及其在多种B细胞肿瘤中的早期临床研究进展。

关键词: B细胞活化因子受体, 嵌合抗原受体T细胞, 免疫疗法, B细胞肿瘤

Abstract: B cell-activating factor receptor(BAFF-R)is relatively stably expressed in various mature B-cell-derived tumors and is involved in maintaining the survival of tumor clones.Compared to traditional targets(such as CD19,etc.),BAFF-R is less likely to lead to immune escape due to antigen downregulation or loss,making it a promising immunotherapy target.In recent years,cellular immunotherapy targeting BAFF-R has gradually moved from experimental research to clinical applications,with chimeric antigen receptor T-cell(CAR-T)therapy emerging as a promising component of immunotherapy for B-cell tumors.This review will systematically elaborate on the biological basis of BAFF-R,the construction strategies of CAR-T,and the early clinical research progress of BAFF-R in various B-cell tumors.

Key words: B cell-activating factor receptor, chimeric antigen receptor T cell, immunotherapy, B cell malignancies

中图分类号:

R733

苏帅, 肖毅. BAFF-R CAR-T治疗B细胞肿瘤的研究进展[J]. 实用肿瘤学杂志, 2026, 40(1): 64-68.

SU Shuai, XIAO Yi. Research progress on BAFF-R CAR-T therapy for B cell malignancies[J]. Journal of Practical Oncology, 2026, 40(1): 64-68.

参考文献

1 Lin H,Yang X,Ye S,et al.Antigen escape in CAR-T cell therapy:mechanisms and overcoming strategies[J].Biomed Pharmacother,2024,178:117252.
2 Rodig S J,Shahsafaei A,Li B,et al.BAFF-R,the major B cell-activating factor receptor,is expressed on most mature B cells and B-cell lymphoproliferative disorders[J].Hum Pathol,2005,36(10):1113-1119.
3 Smulski C R,Eibel H.BAFF and BAFF-receptor in B cell selection and survival[J].Front Immunol,2018,9:2285.
4 Almaden JV,Liu YC,Yang E,et al.B-cell survival and development controlled by the coordination of NF-κB family members RelB and cRel[J].Blood,2016,127(10):1276-1286.
5 Qin H,Dong Z,Wang X,et al.CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies[J].Sci Transl Med,2019,11(511):eaaw9414.
6 Luo Y,Qie Y,Gadd ME,et al.Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies[J].Cancer Immunol Immunother,2023,72(12):4031-4047.
7 Wang X,Dong Z,Awuah D,et al.CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia[J].Leukemia,2022,36(4):1015-1024.
8 Wong DP,Roy NK,Zhang K,et al.A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers[J].Nat Commun,2022,13(1):217.
9 Dong Z,Budde LE,Oh E,et al.Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies[J].Blood Adv,2024,8(15):4066-4076.
10 Del Real MM,Baird JH,Chen L,et al.Favorable safety profile and durable responses to PMB-CT01(BAFFR-CAR T cell)therapy in patients with B-cell lymphomas ineligible for or who failed CD19-targeted therapy,including CD19-negative disease[J].Blood,2024,144:3127.
11 Budde LE,Del Real M,Baird JH,et al.PMB-CT01(BAFFR-CAR T cell)therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy,including CD19-negative disease[J].J Clin Oncol,2024,42(16_suppl):6534-6534.
12 Caimi P,Spear MA,Liter J,et al.244A phase 1 study of novel transposon-based BAFF CAR-T cells(LMY-920)for treatment of relapsed or refractory non-hodgkin lymphoma(NHL)[J].Regular and Young Investigator Award Abstracts,2024:A282-A282.
13 Takahata H,Ohara N,Ichimura K,et al.BAFF-R is expressed on B-cell lymphomas depending on their origin,and is related to proliferation index of nodal diffuse large B-cell lymphomas[J].J Clin Exp Hematop,2010,50(2):121-127.
14 Zhang K,Roy NK,Vicioso Y,et al.BAFF receptor antibody for mantle cell lymphoma therapy[J].Oncoimmunology,2021,10(1):1893501.
15 Li YJ,Jiang WQ,Rao HL,et al.Expression of BAFF and BAFF-R in follicular lymphoma:correlation with clinicopathologic characteristics and survival outcomes[J].PLoS One,2012,7(12):e50936.
16 Xu X,Sun Q,Liang X,et al.Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies[J].Front Immunol,2019,10:2664.
17 Todorovic Z,Todorovic D,Markovic V,et al.CAR T cell therapy for chronic lymphocytic leukemia:successes and shortcomings[J].Curr Oncol,2022,29(5):3647-3657.
18 Haiat S,Billard C,Quiney C,et al.Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia[J].Immunology,2006,118(3):281-292.
19 Hengeveld PJ,Kersten MJ.B-cell activating factor in the pathophysiology of multiple myeloma:a target for therapy?[J].Blood Cancer J,2015,5(2):e282.
20 Wat J,Barmettler S.Hypogammaglobulinemia after chimeric antigen receptor(CAR)T-cell therapy:characteristics,management,and future directions[J].J Allergy Clin Immunol Pract,2022,10(2):460-466.

[1]	赵璐, 张正凤, 王大臻, 杨柳, 刘泽, 娄长杰. 免疫治疗在实体瘤中的应用现状[J]. 实用肿瘤学杂志, 2024, 38(1): 55-61.
[2]	王思然, 胡伟平. 免疫检查点抑制剂治疗口腔鳞癌的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 79-83.
[3]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[4]	张伟明, 孙坚萍, 赵艳. 共刺激受体:肿瘤免疫疗法的潜在靶点[J]. 实用肿瘤学杂志, 2021, 35(5): 441-446.
[5]	林映羲, 龙雅怡, 傅俊宏, 刘芳, 陈敏敏. 单核/巨噬细胞在非霍奇金淋巴瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 352-356.
[6]	张锐, 王智煜, 文孝婷综述, 赵晖审校. 肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 167-171.

BAFF-R CAR-T治疗B细胞肿瘤的研究进展

Research progress on BAFF-R CAR-T therapy for B cell malignancies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价